Device Trial Radar · NCT04294446
Post-market Study of the Biodesign Hernia Graft
Last checked: Nov 20, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
74
Actual
Start
Nov 10, 2020
Primary completion
Nov 26, 2024
Study completion Nov 26, 2024
Sponsor
- Lead sponsor
- Cook Biotech IncorporatedNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 4, 2020
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to collect data on the performance of the Biodesign® Hernia Graft when used to reinforce soft tissues during ventral hernia repair.
Conditions
- Ventral Hernia
Interventions
Biodesign Hernia GraftDevice
The Biodesign Hernia Graft is comprised of 8 layers of decellularized porcine small intestinal submucosa (SIS) that has been pressed-lyophilized (i.e., freeze-dried under vacuum pressure) to laminate the component sheets (i.e., layers) together. In addition, it is perforated and sewn with 4-0 Trisorb suture (polyglycolic acid (PGA); Samyang Corporation, Seoul, South Korea). The suture is distributed in a diamond pattern across the graft and along the periphery and is intended to mitigate delamination of the layers upon rehydration and/or manipulation during implantation. Being a completely biologic device, the Biodesign Hernia Graft is considered MR safe.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hernia RecurrenceTime frame: 1-year
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Vanderbilt University Medical Center
Nashville, Tennessee
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.